Skip to main content
Top
Published in: Archives of Osteoporosis 1/2017

01-12-2017 | Original Article

Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis

Authors: Elisa Martín-Merino, Consuelo Huerta-Álvarez, Daniel Prieto-Alhambra, Dolores Montero-Corominas

Published in: Archives of Osteoporosis | Issue 1/2017

Login to get access

Abstract

Summary

Among 95,057 patients ≥50 years with new anti-osteoporosis medications (AOM) (2001–2013) in primary care, 1-year cessation was 51% (28%–68%), higher in men, smokers, patients with missing lifestyle data, and out normal BMI, and lower in those aged 60–79, with recent fractures or other anti-osteoporotics, suggesting non-severe osteoporosis and less risk awareness.

Purpose

Low compliance to anti-osteoporosis medications (AOM) has been previously reported. We aimed to estimate 1-year cessation rates of different AOMs as used in Spanish healthcare settings, and to identify associated risk factors.

Methods

A cohort study was performed using primary care records data (BIFAP). Patients entered the cohort when aged 50 years in 2001–2013, with ≥1 year of data available, and identified as incident users of AOM (1-year washout). Participants were divided into six cohorts: alendronate, other oral bisphosphonates, selective oestrogen receptor modulators, strontium ranelate, teriparatide, and denosumab. Patients were followed from therapy initiation to the earliest of cessation (90-day refill gap), switching (to alternative AOM), loss to follow-up, death, or end of 2013. One-year therapy cessation was estimated using life tables. Hazard ratios (of cessation) according to age, sex, lifestyle factors, morbidity, and co-medication were estimated after stepwise backwards selection.

Results

A total of 95,057 AOM users were identified (91% women; mean age 68). One-year cessation was 51% overall, highest for strontium ranelate (68%), and lowest for denosumab (28%). Cessation probability was higher in men (14% to 2.1-fold), smokers (>6%), and patients with missing BMI (19–28%) or smoking (6–20%) data, and overweight/obese/underweight (7% to 2.6-fold increase compared to normal weight). Patients aged 60–79 years, with a recent fracture or other drugs used for osteoporosis, had better persistence.

Conclusions

Over half of the patients initiating AOM stopped therapy within the first year after initiation. The described risk factors for cessation could be proxies for non-severe osteoporosis, and/or disease/risk awareness, which could inform the targeting of high-risk patients for monitoring and/or interventions aimed at improving persistence.
Literature
1.
go back to reference Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al (1996 Dec 7) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet Lond Engl 348(9041):1535–1541CrossRef Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al (1996 Dec 7) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet Lond Engl 348(9041):1535–1541CrossRef
2.
go back to reference Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC et al (2000 Nov) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85(11):4118–4124CrossRefPubMed Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC et al (2000 Nov) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85(11):4118–4124CrossRefPubMed
3.
go back to reference Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al (1999 Aug 18) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282(7):637–645CrossRefPubMed Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al (1999 Aug 18) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282(7):637–645CrossRefPubMed
4.
go back to reference Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD et al (2004 Jan 29) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350(5):459–468CrossRefPubMed Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD et al (2004 Jan 29) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350(5):459–468CrossRefPubMed
5.
go back to reference Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD (2009 Apr) Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res Off J Am Soc Bone Miner Res 24(4):719–725CrossRef Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD (2009 Apr) Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res Off J Am Soc Bone Miner Res 24(4):719–725CrossRef
6.
go back to reference Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B et al (2005 Aug) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res Off J Am Soc Bone Miner Res 20(8):1315–1322CrossRef Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B et al (2005 Aug) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res Off J Am Soc Bone Miner Res 20(8):1315–1322CrossRef
7.
go back to reference Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al (2001 May 10) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434–1441CrossRefPubMed Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al (2001 May 10) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434–1441CrossRefPubMed
8.
go back to reference Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V et al (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1:CD001155 Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V et al (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1:CD001155
9.
go back to reference Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V et al (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1:CD004523 Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V et al (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1:CD004523
10.
go back to reference Reyes C, Pottegård A, Schwarz P, Javaid MK, Van Staa TP, Cooper C, et al. 2016 Real-life and RCT participants: alendronate users versus FITs’ trial eligibility criterion. Calcif Tissue Int. Reyes C, Pottegård A, Schwarz P, Javaid MK, Van Staa TP, Cooper C, et al. 2016 Real-life and RCT participants: alendronate users versus FITs’ trial eligibility criterion. Calcif Tissue Int.
11.
go back to reference Siris ES, Selby PL, Saag KG, Borgström F, Herings RMC, Silverman SL (2009 Feb) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122(2 Suppl):S3–13CrossRefPubMed Siris ES, Selby PL, Saag KG, Borgström F, Herings RMC, Silverman SL (2009 Feb) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122(2 Suppl):S3–13CrossRefPubMed
12.
go back to reference Carbonell-Abella C, Pages-Castella A, Javaid MK, Nogues X, Farmer AJ, Cooper C et al (2015 Jul) Early (1-year) discontinuation of different anti-osteoporosis medications compared: a population-based cohort study. Calcif Tissue Int 23 Carbonell-Abella C, Pages-Castella A, Javaid MK, Nogues X, Farmer AJ, Cooper C et al (2015 Jul) Early (1-year) discontinuation of different anti-osteoporosis medications compared: a population-based cohort study. Calcif Tissue Int 23
13.
go back to reference Tosteson ANA, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM et al (2003 Aug 15) Early discontinuation of treatment for osteoporosis. Am J Med 115(3):209–216CrossRefPubMed Tosteson ANA, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM et al (2003 Aug 15) Early discontinuation of treatment for osteoporosis. Am J Med 115(3):209–216CrossRefPubMed
14.
go back to reference Penning-van Beest FJA, Goettsch WG, Erkens JA, Herings RMC (2006 Feb) Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 28(2):236–242CrossRefPubMed Penning-van Beest FJA, Goettsch WG, Erkens JA, Herings RMC (2006 Feb) Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 28(2):236–242CrossRefPubMed
15.
go back to reference Turbí C, Herrero-Beaumont G, Acebes JC, Torrijos A, Graña J, Miguélez R et al (2004 Feb) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 26(2):245–256CrossRefPubMed Turbí C, Herrero-Beaumont G, Acebes JC, Torrijos A, Graña J, Miguélez R et al (2004 Feb) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 26(2):245–256CrossRefPubMed
16.
go back to reference Salgueiro ME, Manso G, Castells X, Jimeno FJ, Ordoñez L, González V et al (2013 Jan) Trends in the pharmacological treatment of osteoporosis in Spain from 2000 to 2008. Maturitas 74(1):74–78CrossRefPubMed Salgueiro ME, Manso G, Castells X, Jimeno FJ, Ordoñez L, González V et al (2013 Jan) Trends in the pharmacological treatment of osteoporosis in Spain from 2000 to 2008. Maturitas 74(1):74–78CrossRefPubMed
17.
go back to reference White HJ, Bettiol SS, Perera R, Roberts NW, Javaid MK, Farmer AJ (2010 Dec) A systematic review assessing the effectiveness of interventions to improve persistence with anti-resorptive therapy in women at high risk of clinical fracture. Fam Pract 27(6):593–603CrossRefPubMed White HJ, Bettiol SS, Perera R, Roberts NW, Javaid MK, Farmer AJ (2010 Dec) A systematic review assessing the effectiveness of interventions to improve persistence with anti-resorptive therapy in women at high risk of clinical fracture. Fam Pract 27(6):593–603CrossRefPubMed
19.
go back to reference World Organisation of National Colleges, Academic & Academic Associations of General Practitioners/Family Physicians (1998). The international classification of primary care. Oxford: Oxford University Press. World Organisation of National Colleges, Academic & Academic Associations of General Practitioners/Family Physicians (1998). The international classification of primary care. Oxford: Oxford University Press.
20.
go back to reference Gardarsdottir H, Souverein PC, Egberts TCG, Heerdink ER (2010 Apr) Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length. J Clin Epidemiol 63(4):422–427CrossRefPubMed Gardarsdottir H, Souverein PC, Egberts TCG, Heerdink ER (2010 Apr) Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length. J Clin Epidemiol 63(4):422–427CrossRefPubMed
21.
go back to reference Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM et al (2005) Compliance with osteoporosis medications. Arch Intern Med 165(20):2414–2419CrossRefPubMed Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM et al (2005) Compliance with osteoporosis medications. Arch Intern Med 165(20):2414–2419CrossRefPubMed
22.
go back to reference Vicente Molinero A, Lou Arnal S, Medina Orgaz E, Muñoz Jacobo S, Antonio Ibáñez Estrella J (2011 Feb) Osteoporosis treatment with biphosphonates: approaches to care reality. Atencion Primaria Soc Esp Med Fam Comunitaria. 43(2):95–99CrossRef Vicente Molinero A, Lou Arnal S, Medina Orgaz E, Muñoz Jacobo S, Antonio Ibáñez Estrella J (2011 Feb) Osteoporosis treatment with biphosphonates: approaches to care reality. Atencion Primaria Soc Esp Med Fam Comunitaria. 43(2):95–99CrossRef
23.
go back to reference de Felipe R, Cáceres C, Cimas M, Dávila G, Fernández S, Ruiz T (2010 Nov) Clinical characteristics of patients under treatment for osteoporosis in a primary care centre. Who do we treat? Atencion Primaria Soc Esp Med Fam Comunitaria 42(11):559–563CrossRef de Felipe R, Cáceres C, Cimas M, Dávila G, Fernández S, Ruiz T (2010 Nov) Clinical characteristics of patients under treatment for osteoporosis in a primary care centre. Who do we treat? Atencion Primaria Soc Esp Med Fam Comunitaria 42(11):559–563CrossRef
24.
go back to reference Roerholt C, Eiken P, Abrahamsen B (2009 Feb) Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 20(2):299–307CrossRef Roerholt C, Eiken P, Abrahamsen B (2009 Feb) Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 20(2):299–307CrossRef
25.
go back to reference Imaz, I. (2010) Análisis coste-utilidad de los tratamientos farmacológicos para la prevención de frac- turas en mujeres con osteoporosis en ESPAÑA. Madrid: Agencia de Evaluación de Tecnologías Sanitarias (AETS). Instituto de Salud Carlos III- Ministerio de Ciencia e Innovación Imaz, I. (2010) Análisis coste-utilidad de los tratamientos farmacológicos para la prevención de frac- turas en mujeres con osteoporosis en ESPAÑA. Madrid: Agencia de Evaluación de Tecnologías Sanitarias (AETS). Instituto de Salud Carlos III- Ministerio de Ciencia e Innovación
26.
go back to reference Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM (2010 Nov) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 21(11):1943–1951CrossRef Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM (2010 Nov) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 21(11):1943–1951CrossRef
27.
go back to reference Harrington JT, Ste-Marie L-G, Brandi ML, Civitelli R, Fardellone P, Grauer A et al (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74(2):129–135CrossRefPubMed Harrington JT, Ste-Marie L-G, Brandi ML, Civitelli R, Fardellone P, Grauer A et al (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74(2):129–135CrossRefPubMed
28.
go back to reference Roux C, Seeman E, Eastell R, Adachi J, Jackson RD, Felsenberg D et al (2004 Apr) Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20(4):433–439CrossRefPubMed Roux C, Seeman E, Eastell R, Adachi J, Jackson RD, Felsenberg D et al (2004 Apr) Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20(4):433–439CrossRefPubMed
38.
go back to reference Klop C, Welsing PMJ, Elders PJM, Overbeek JA, Souverein PC, Burden AM et al (2015) Long-term persistence with anti-osteoporosis drugs after fracture. Osteoporos Int 26(6):1831–1840CrossRefPubMedPubMedCentral Klop C, Welsing PMJ, Elders PJM, Overbeek JA, Souverein PC, Burden AM et al (2015) Long-term persistence with anti-osteoporosis drugs after fracture. Osteoporos Int 26(6):1831–1840CrossRefPubMedPubMedCentral
39.
go back to reference Amaya MC, Gómez MM, Martínez MJ, Lendínez JM. Adecuación del tratamiento preventivo de fracturas osteoporóticas en mujeres posmenopáusicas. SEMERGEN - Med Fam. :121–7. Amaya MC, Gómez MM, Martínez MJ, Lendínez JM. Adecuación del tratamiento preventivo de fracturas osteoporóticas en mujeres posmenopáusicas. SEMERGEN - Med Fam. :121–7.
40.
go back to reference Cantudo-Cuenca MR, Calvo-Cidoncha E, Robustillo-Cortés MA, Saborido-Cansino MC, Gómez-Estrella G, Sánchez-Pedrosa A (2016 Jan) Suitability of strontium ranelate in a health care management area after drug surveillance alerts. Aten Primaria 48(1):49–53CrossRefPubMed Cantudo-Cuenca MR, Calvo-Cidoncha E, Robustillo-Cortés MA, Saborido-Cansino MC, Gómez-Estrella G, Sánchez-Pedrosa A (2016 Jan) Suitability of strontium ranelate in a health care management area after drug surveillance alerts. Aten Primaria 48(1):49–53CrossRefPubMed
41.
go back to reference Carbonell AC (2011 Jun) La osteoporosis en Atención Primaria. Rev Osteoporos Metab Miner. 3(2):73–74 Carbonell AC (2011 Jun) La osteoporosis en Atención Primaria. Rev Osteoporos Metab Miner. 3(2):73–74
42.
go back to reference Blanch J, Casado E, González J, Valdés C, Ruiz-Baena J, Palomino R et al (2016 Mar) Percepción de los profesionales médicos respecto la adherencia terapéutica de los pacientes con osteoporosis. Rev Osteoporos Metab Miner 8(1):15–23 Blanch J, Casado E, González J, Valdés C, Ruiz-Baena J, Palomino R et al (2016 Mar) Percepción de los profesionales médicos respecto la adherencia terapéutica de los pacientes con osteoporosis. Rev Osteoporos Metab Miner 8(1):15–23
43.
go back to reference Gifre L, Monegal A, Filella X, Muxi A, Guañabens N, Peris P (2015). Factores relacionados con la respuesta inadecuada al tratamiento osteoformador (teriparatida/PTH 1–84) en pacientes con osteoporosis severa. Resultados preliminares. Rev Osteoporos Metab Miner [Internet]. [cited 2016 Dec 19]; Available from: http://www.redalyc.org/articulo.oa?id=360943612002 Gifre L, Monegal A, Filella X, Muxi A, Guañabens N, Peris P (2015). Factores relacionados con la respuesta inadecuada al tratamiento osteoformador (teriparatida/PTH 1–84) en pacientes con osteoporosis severa. Resultados preliminares. Rev Osteoporos Metab Miner [Internet]. [cited 2016 Dec 19]; Available from: http://​www.​redalyc.​org/​articulo.​oa?​id=​360943612002
44.
go back to reference Kearney DM, Lockey RF (2006) Osteoporosis and asthma. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol 96(6):769–774 778, 857 CrossRef Kearney DM, Lockey RF (2006) Osteoporosis and asthma. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol 96(6):769–774 778, 857 CrossRef
Metadata
Title
Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis
Authors
Elisa Martín-Merino
Consuelo Huerta-Álvarez
Daniel Prieto-Alhambra
Dolores Montero-Corominas
Publication date
01-12-2017
Publisher
Springer London
Published in
Archives of Osteoporosis / Issue 1/2017
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-017-0331-6

Other articles of this Issue 1/2017

Archives of Osteoporosis 1/2017 Go to the issue